ArticleImmunity2018
The Tumor Necrosis Factor Superfamily Member RANKL Suppresses Effector Cytokine Production in Group 3 Innate Lymphoid Cells.
Article in Immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 85 citations in OpenAlex.
- Peyer's patch M cells organize an epithelial niche that sustains group 3 innate lymphoid cells and IL-22.Nature immunology · 2026Article
- Antigen-sampling gut cells moonlight as organizers of immune defense.Nature immunology · 2026Article
- Rank-dependent control of tuft and BEST4 cell development in the intestine.Nature communications · 2026Article
- Article
- Resident microbes shape host immunity and protect against pathogen infection and inflammatory disease.Cellular and molecular life sciences : CMLS · 2026Review
- Dendritic Cell-Based Cancer Vaccines: The Impact of Modulating Innate Lymphoid Cells on Anti-Tumor Efficacy.Cells · 2025Review
- Enteric GABAergic neuron-derived γ-aminobutyric acid initiates expression of Igfbp7 to sustain ILC3 homeostasis.Nature immunology · 2025Article
- Natural killer cells in skin: a unique opportunity to better characterize the many facets of an overlooked secondary lymphoid organ.Frontiers in immunology · 2025Review
- TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti-PD-1 tumor immunotherapy.Science immunology · 2024Article
- The IRE1α/XBP1 pathway sustains cytokine responses of group 3 innate lymphoid cells in inflammatory bowel disease.The Journal of clinical investigation · 2024Article
- Sirtuin 6 inhibits group 3 innate lymphoid cell function and gut immunity by suppressing IL-22 production.Frontiers in immunology · 2024Article
- mTORC2 acts as a gatekeeper for mTORC1 deficiency-mediated impairments in ILC3 development.Acta pharmacologica Sinica · 2023Article
- A Cre-deleter specific for embryo-derived brain macrophages reveals distinct features of microglia and border macrophages.Immunity · 2023Article
- Denosumab Is Superior to Raloxifene in Lowering Risks of Mortality and Ischemic Stroke in Osteoporotic Women.Pharmaceuticals (Basel, Switzerland) · 2023Article
- ILC3: a case of conflicted identity.Frontiers in immunology · 2023Review
- Single-cell landscape dissecting the transcription and heterogeneity of innate lymphoid cells in ischemic heart.Frontiers in immunology · 2023Article
- Inflammatory Cytokines That Enhance Antigen Responsiveness of Naïve CD8International journal of molecular sciences · 2022Article
- Review
- Clostridioides difficile Toxin B Activates Group 3 Innate Lymphocytes.Infection and immunity · 2022Article
- Innate Lymphoid Cells and Inflammatory Bowel Disease.Advances in experimental medicine and biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
Abstract
While signals that activate group 3 innate lymphoid cells (ILC3s) have been described, the factors that negatively regulate these cells are less well understood. Here we found that the tumor necrosis factor (TNF) superfamily member receptor activator of nuclear factor κB ligand (RANKL) suppressed ILC3 activity in the intestine. Deletion of RANKL in ILC3s and T cells increased C-C motif chemokine receptor 6 (CCR6)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.